Influenza Diagnostics Development and Distribution ...httpAssets)/90518F...First Diagnostic Kits...
Transcript of Influenza Diagnostics Development and Distribution ...httpAssets)/90518F...First Diagnostic Kits...
Influenza Diagnostics Development and Distribution:
Responding to Emerging Threats
Michael W. Shaw, PhDInfluenza DivisionNational Center for Immunization and Respiratory Diseases
Actions for Diagnostic Preparedness:
• Develop New Diagnostic Tests and Improved Diagnostic Capabilities
• Improve Surge Capacity• Implement Challenge and Proficiency Testing• Develop Regulatory Preparedness• Improve Access to Tests and Reagents• Provide Guidance for Clinicians• Improve Virologic Surveillance
Serology(AntibodyDetection)
Immunofluorescence (Virus Detection)
WHO(GISRS)
Outpatient& Clinic
HospitalLab
ReferralLab
PublicHealth
Lab
Virus Culture
Immunoassay(Virus Detection)
CU
RR
ENT
TEST
S
Real-time RT-PCR(Identification of Virus)
Improved Point-of-Care
Influenza Tests
Laboratory Influenza Test
TEST
S IN
D
EVEL
OPM
ENT
Rapid Influenza Immunity Test
TEST
SE
TTIN
GS
Antiviral Resistance Influenza Test
What Tests are Needed and Where Do We Use Them?Antigenic Characterization(Determine Vaccine Match)
Gaps in Influenza Diagnostic Testing
• No simple, rapid test available for use in point-of-care clinical setting to differentiate novel influenza from seasonal strains• Confirmation of subtype requires submission of
specimens to a laboratory capable of running high-complexity tests
• Current rapid tests are not easily adaptable for inclusion of new, variant strains
• No tests available for antiviral resistance suitable for patient care decisions
Real-Time RT-PCR for InfluenzaReal-Time RT-PCR for Influenza
• Based on CDC Assay cleared by FDA for domestic US use
• Capable of detecting all influenza A and B• Identifies Influenza A subtypes:
• Seasonal H1 and H3• Novel subtypes as needed
• H5• H7
• Internal Controls to test quality of specimen and proper test conditions – ensures test is valid
High-complexity assay only suitable for labs with appropriate equipment and trained personnel
• Based on CDC Assay cleared by FDA for domestic US use
• Capable of detecting all influenza A and B• Identifies Influenza A subtypes:
• Seasonal H1 and H3• Novel subtypes as needed
• H5• H7
• Internal Controls to test quality of specimen and proper test conditions – ensures test is valid
High-complexity assay only suitable for labs with appropriate equipment and trained personnel
The Influenza Reagent Resource (IRR):A global CDC resource for public health laboratories
• Goals:• Support global influenza surveillance by
supplying high quality test kits for the detection and characterization of influenza
• Ensure high quality reagents are the standard for influenza research and the development of new influenza diagnostics, vaccines, and therapeutics
IRR
VirusSurveillance
Researchand
Development
Registrants order reagents through an email box ([email protected]) or web
(http://influenzareagentresource.org)
As of Summer, 2013, the CDC IRR has distributed over 16,000 reagents to 665
laboratories in 161 countries
New diagnostic tests and reagents are developed and distributed as needed
when new virus variants appear.
April 15First caseIdentifiedA/California/4/2009
April 29First DiagnosticKits Shipped toState Labs
May 3First DiagnosticKits Shipped toWHO Network
May 23Vaccine StrainShipped toManufacturers
First cases in Mexico: Late February–Early March
April 15First caseIdentifiedA/California/4/2009
April 29First DiagnosticKits Shipped toState Labs
May 3First DiagnosticKits Shipped toWHO Network
May 23Vaccine StrainShipped toManufacturers
March 31Novel Virus Identified,Sequences Made PublicBy China CDC
April 11First H7N9 VirusShipped to CDCBy China CDC
April 25First DiagnosticKits Shipped
May 2Vaccine StrainShipped toManufacturers
Timeline for Response to 2013 H7N9 Outbreak:
Timeline for Response to 2009 H1N1 Pandemic:
CDC H7 rRT-PCR Kit Shipments(As of 26 July, 2013)
# of US Domestic Requests
# of US Domestic Labs
# of International Requests
# of International
Labs
# of Countries
Shipped 109 108 78 73 69Pending 1 1 11 11 11Total 110 109 89 84 80
CDC Protocol Availability
• CDC protocols including all primer and probe sequences posted on WHO website(http://www.who.int/influenza/resources/en/):• Real-time RT-PCR diagnosis influenza• Pyrosequencing for markers of antiviral
sensitivity/resistance• Full genome sequencing of influenza viruses• REGULAR UPDATES AS PROTOCOLS
MODIFIED TO IMPROVE PERFORMANCE
• Laboratories worldwide have used these to develop their own testing protocols
The IRR stocks many influenza specific reagents
• rRT-PCR kits and reagents• WHO test kits to identify influenza• Reference influenza viruses • Antibodies to detect influenza• Virus and antibody assay reagents• Sequencing reagents• Standards for test development
Who can receive IRR reagents?• Qualified public health laboratories and WHO National
Influenza Centers• Non-NIC public health and other non-profit
laboratories are considered on a case-by-case basis
How are reagents distributed to users?
• All products are provided free of charge, the IRR does not cover customs fees
• International shipments are delivered within 2 weeks to most locations
• Customer support is available at [email protected]• Customer support is managed by CDC and ATCC
• Technical support for rRT-PCR diagnostics is available at [email protected]• Technical support is managed by CDC
• Technical support for other reagents is available by contacting CDC subject matter experts
Conclusions
Influenza is both a recurrent, seasonal disease and a proven, emergent threat requiring constant international surveillance.
The natural variation of influenza viruses means diagnostic tests must be updated frequently to detect newly emergent strains.
Because influenza can spread rapidly both in human and animal hosts, public health laboratories need access to the most current tests as quickly as possible.